Risks of covid-19 hospital admission and death for people with learning disability: population based cohort study using the OpenSAFELY platform

Abstract

Objective To assess the association between learning disability and risk of hospital admission and death from covid-19 in England among adults and children. Design Population based cohort study on behalf of NHS England using the OpenSAFELY platform. Setting Patient level data were obtained for more than 17 million people registered with a general practice in England that uses TPP software. Electronic health records were linked with death data from the Office for National Statistics and hospital admission data from NHS Secondary Uses Service. Participants Adults (aged 16-105 years) and children (<16 years) from two cohorts: wave 1 (registered with a TPP practice as of 1 March 2020 and followed until 31 August 2020); and wave 2 (registered 1 September 2020 and followed until 8 February 2021). The main exposure group consisted of people on a general practice learning disability register; a subgroup was defined as those having profound or severe learning disability. People with Down’s syndrome and cerebral palsy were identified (whether or not they were on the learning disability register). Main outcome measure Covid-19 related hospital admission and covid-19 related death. Non-covid-19 deaths were also explored. Results For wave 1, 14 312 023 adults aged ≥16 years were included, and 90 307 (0.63%) were on the learning disability register. Among adults on the register, 538 (0.6%) had a covid-19 related hospital admission; there were 222 (0.25%) covid-19 related deaths and 602 (0.7%) non-covid deaths. Among adults not on the register, 29 781 (0.2%) had a covid-19 related hospital admission; there were 13 737 (0.1%) covid-19 related deaths and 69 837 (0.5%) non-covid deaths. Wave 1 hazard ratios for adults on the learning disability register (adjusted for age, sex, ethnicity, and geographical location) were 5.3 (95% confidence interval 4.9 to 5.8) for covid-19 related hospital admission and 8.2 (7.2 to 9.4) for covid-19 related death. Wave 2 produced similar estimates. Associations were stronger among those classified as having severe to profound learning disability, and among those in residential care. For both waves, Down’s syndrome and cerebral palsy were associated with increased hazards for both events; Down’s syndrome to a greater extent. Hazard ratios for non-covid deaths followed similar patterns with weaker associations. Similar patterns of increased relative risk were seen for children, but covid-19 related deaths and hospital admissions were rare, reflecting low event rates among children. Conclusions People with learning disability have markedly increased risks of hospital admission and death from covid-19, over and above the risks observed for non-covid causes of death. Prompt access to covid-19 testing and healthcare is warranted for this vulnerable group, and prioritisation for covid-19 vaccination and other targeted preventive measures should be considered.

Trends and clinical characteristics of COVID-19 vaccine recipients: a federated analysis of 57.9 million patients' primary care records in situ using OpenSAFELY

“…In late February the JCVI recommended expanded vaccine access for all people on the GP learning disability register as well as adults with other related conditions, including cerebral palsy. This update of the previous advice was based on OpenSAFELY analysis showing a higher risk of mortality in those with learning disabilities 39 and the JCVI anticipated that an additional 150 000 people would receive the vaccine sooner as a result of this advice. 40…”

The Impact of Risk-Adjusted Heparin Regimens on the Outcome of Patients with COVID-19 Infection. A Prospective Cohort Study

“…Indeed, despite the lack of a control population the rate of VTE complications we found in our patients (approximately 10%) is lower than that reported in patients managed without any thromboprophylaxis [ 16 ]. More significantly, heparin prophylaxis has been reported to improve the prognosis of patients with the COVID-19 disease remarkably, irrespective of the treatment dose [ 17 , 18 ]. As recent data suggest that therapeutic doses of heparin are likely to improve the prognosis of patients with moderate infection [ 19 , 20 , 21 , 22 ], in this category of patients the choice remains between therapeutic and prophylactic doses.…”

COVID-19 in Multiple Sclerosis: Clinically reported outcomes from the UK Multiple Sclerosis Register

“…Certainly, during the first wave there remains a concern about how decisions regarding treatment were made for those at-risk populations e. g. those above a certain age but also those with prior disabilities. These decisions were managed more cohesively following guidance for the second wave (Williamson et al, 2021;.…”